CCCC
C4 Therapeutics Inc

2,391
Mkt Cap
$187.04M
Volume
1.42M
52W High
$4.22
52W Low
$1.09
PE Ratio
-1.21
CCCC Fundamentals
Price
$2.03
Prev Close
$1.93
Open
$2.00
50D MA
$2.38
Beta
1.98
Avg. Volume
1.87M
EPS (Annual)
-$1.52
P/B
0.98
Rev/Employee
$323,490.91
Loading...
Loading...
News
all
press releases
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 7,172,653...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC)
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 5,066 call options on the company. This is an...
MarketBeat·20d ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One...
MarketBeat·24d ago
News Placeholder
FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst
C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Investment analysts at Brookline Capital Management decreased their FY2028 EPS estimates for C4 Therapeutics in a report issued on Thursday...
MarketBeat·2mo ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Issues Quarterly Earnings Results
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47...
MarketBeat·2mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +6.38% and +72.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of +41.67% and +2.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Precision Oncology Approaches Drive $312B Market Transformation
Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...
PR Newswire·3mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest CCCC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.